Little enhancement of meal-induced glucagon-like peptide 1 secretion in Japanese: Comparison of type 2 diabetes patients and healthy controls

被引:77
作者
Yabe, Daisuke [1 ]
Kuroe, Akira [1 ]
Lee, Soushou [2 ]
Watanabe, Koin [1 ]
Hyo, Takanori [1 ]
Hishizawa, Masahiro [1 ]
Kurose, Takeshi [1 ]
Deacon, Carolyn F. [3 ]
Holst, Jens J. [3 ]
Hirano, Tsutomu [2 ]
Inagaki, Nobuya [4 ]
Seino, Yutaka [1 ]
机构
[1] Kansai Elect Power Hosp, Div Diabet Clin Nutr & Endocrinol, Osaka, Japan
[2] Showa Univ, Sch Med, Dept Diabet Metab & Endocrinol, Tokyo 142, Japan
[3] Univ Copenhagen, Dept Biomed Sci, Copenhagen, Denmark
[4] Kyoto Univ, Grad Sch Med, Dept Diabet & Clin Nutr, Kyoto, Japan
关键词
DPP-4; GIP; GLP-1; GASTRIC-INHIBITORY POLYPEPTIDE; INCRETIN RESPONSES; MELLITUS; INSULIN; GLUCOSE; PLASMA; DEGRADATION; PRODUCTS; EFFICACY; HORMONES;
D O I
10.1111/j.2040-1124.2010.00010.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Although glucose-dependent insulinotropic polypeptide (GIP) levels have been characterized previously, GLP-1 levels in Asians remain unclear. Here, we investigate total and intact levels of GLP-1, as well as GIP during oral glucose and meal tolerance tests (OGTT and MTT) in Japanese patients with or without type 2 diabetes (T2DM). Seventeen Japanese healthy controls and 18 age-matched and untreated patients with T2DM of short duration participated in the present study. Fasting levels of total GPL-1 were similar between the two groups (approximately 15 pM), and intact GLP-1 levels were considerably low in both groups (less than 1 pM). In both groups, total GLP-1 reached a peak 30 min after glucose ingestion (30-40 pM), whereas intact GLP-1 levels remained low with no significant peak. In MTT, total and intact GLP-1 showed no obvious peak. The current data indicate that intact GLP-1 levels are considerably low in the Japanese and that meal-induced enhancement of GLP-1 secretion is negligible in the Japanese. (J Diabetes Invest, doi: 10.1111/j.2040-1124.2010.00010.x, 2010)
引用
收藏
页码:56 / 59
页数:4
相关论文
共 26 条
  • [1] Efficacy and safety of incretin therapy in type 2 diabetes - Systematic review and meta-analysis
    Amori, Renee E.
    Lau, Joseph
    Pittas, Anastassios G.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 298 (02): : 194 - 206
  • [2] Incretin and islet hormonal responses to fat and protein ingestion in healthy men
    Carr, Richard D.
    Larsen, Marianne O.
    Winzell, Maria Sorhede
    Jelic, Katarina
    Lindgren, Ola
    Deacon, Carolyn F.
    Ahren, Bo
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2008, 295 (04): : E779 - E784
  • [3] Immunoassays for the incretin hormones GIP and GLP-1
    Deacon, Carolyn F.
    Holst, Jens J.
    [J]. BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2009, 23 (04) : 425 - 432
  • [4] Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide
    Deacon, CF
    Nauck, MA
    Meier, J
    Hücking, K
    Holst, JJ
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (10) : 3575 - 3581
  • [5] The biology of incretin hormones
    Drucker, DJ
    [J]. CELL METABOLISM, 2006, 3 (03) : 153 - 165
  • [6] The physiology of glucagon-like peptide 1
    Holst, Jens Juul
    [J]. PHYSIOLOGICAL REVIEWS, 2007, 87 (04) : 1409 - 1439
  • [7] Postprandial glucose, insulin, and incretin responses to grain products in healthy subjects
    Juntunen, KS
    Niskanen, LK
    Liukkonen, KH
    Poittanen, KS
    Holst, JJ
    Mykkänen, HM
    [J]. AMERICAN JOURNAL OF CLINICAL NUTRITION, 2002, 75 (02) : 254 - 262
  • [8] Vildagliptin dose-dependently improves glycemic control in Japanese patients with type 2 diabetes mellitus
    Kikuchi, Masatoshi
    Abe, Nobuyuki
    Kato, Mitsutoshi
    Terao, Shinji
    Mimori, Nobuyuki
    Tachibana, Hideo
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2009, 83 (02) : 233 - 240
  • [9] THE HETEROGENEITY OF GASTRIC-INHIBITORY POLYPEPTIDE IN PORCINE AND HUMAN GASTROINTESTINAL MUCOSA EVALUATED WITH 5 DIFFERENT ANTISERA
    KRARUP, T
    HOLST, JJ
    [J]. REGULATORY PEPTIDES, 1984, 9 (1-2) : 35 - 46
  • [10] Incretin-based therapies for type 2 diabetes mellitus
    Lovshin, Julie A.
    Drucker, Daniel J.
    [J]. NATURE REVIEWS ENDOCRINOLOGY, 2009, 5 (05) : 262 - 269